$PRVA
Privia Health Group, Inc. Stock $prva

$prva Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000175965522000032 Filed on March 25, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$966.2M	$213.7M	$817.1M
YoY Change	18.25%		3.91%
Cost Of Revenue	$902.6M	$190.3M	$734.5M
YoY Change	22.88%		2.31%
Gross Profit	$63.66M	$23.40M	$82.60M
YoY Change	-22.93%		20.58%
Gross Profit Margin	6.59%	10.95%	10.11%
Selling, General & Admin	$278.6M	$18.78M	$55.36M
YoY Change	403.32%		8.58%
% of Gross Profit	437.68%	80.27%	67.02%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.464M	$452.0K	$1.843M
YoY Change	33.7%		29.15%
% of Gross Profit	3.87%	1.93%	2.23%
Operating Expenses	$1.184B	$19.24M	$791.7M
YoY Change	49.51%		2.78%
Operating Profit	-$217.4M	$4.162M	$25.38M
YoY Change	-956.72%		58.01%
Interest Expense	$1.100M	-$437.0K	$1.900M
YoY Change	-42.11%		-52.5%
% of Operating Profit		-10.5%	7.49%
Other Income/Expense, Net
YoY Change
Pretax Income	-$218.5M	$3.725M	$23.46M
YoY Change	-1031.28%		156.37%
Income Tax	-$27.86M	-$54.00K	-$7.441M
% Of Pretax Income		-1.45%	-31.71%
Net Earnings	-$188.2M	$3.864M	$31.24M
YoY Change	-702.45%		278.99%
Net Earnings / Revenue	-19.48%	1.81%	3.82%
Basic Earnings Per Share	-$1.83		$0.33
Diluted Earnings Per Share	-$1.83	$37.59K	$0.33
COMMON SHARES
Basic Shares Outstanding	103.0M shares		95.95M shares
Diluted Shares Outstanding	103.0M shares		95.95M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$320.6M		$84.60M
YoY Change	278.93%		80.38%
Cash & Equivalents	$320.6M	$84.63M	$84.60M
Short-Term Investments
Other Short-Term Assets	$8.697M		$6.300M
YoY Change	38.05%		16.67%
Inventory
Prepaid Expenses
Receivables	$117.4M	$99.12M	$99.10M
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$446.7M	$190.1M	$190.1M
YoY Change	134.97%		46.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.14M	$4.814M	$4.800M
YoY Change	194.5%		-14.29%
Goodwill		$118.7M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$37.89M	$4.475M	$9.400M
YoY Change	303.03%		64.91%
Total Long-Term Assets	$239.7M	$138.9M	$138.9M
YoY Change	72.57%		-1.21%
TOTAL ASSETS
Total Short-Term Assets	$446.7M	$190.1M	$190.1M
Total Long-Term Assets	$239.7M	$138.9M	$138.9M
Total Assets	$686.4M	$329.0M	$329.0M
YoY Change	108.62%		21.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.973M	$5.235M	$5.200M
YoY Change	-42.83%		940.0%
Accrued Expenses	$45.91M	$31.19M	$31.20M
YoY Change	47.13%		11.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00		$0.00
YoY Change
Long-Term Debt Due	$875.0K		$900.0K
YoY Change	-2.78%		-73.53%
Total Short-Term Liabilities	$190.5M	$146.9M	$146.9M
YoY Change	29.65%		27.52%
LONG-TERM LIABILITIES
Long-Term Debt	$31.69M		$32.80M
YoY Change	-3.39%		-17.38%
Other Long-Term Liabilities	$14.04M	$5.595M	$5.600M
YoY Change	150.77%		14.29%
Total Long-Term Liabilities	$45.73M	$38.38M	$38.40M
YoY Change	19.09%		-13.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$190.5M	$146.9M	$146.9M
Total Long-Term Liabilities	$45.73M	$38.38M	$38.40M
Total Liabilities	$259.5M	$185.3M	$182.2M
YoY Change	42.43%		13.88%
SHAREHOLDERS EQUITY
Retained Earnings		-$19.88M
YoY Change
Common Stock		$960.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$426.9M	$146.7M	$146.7M
YoY Change
Total Liabilities & Shareholders Equity	$686.4M	$329.0M	$329.0M
YoY Change	108.62%		21.76%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$188.2M	$3.864M	$31.24M
YoY Change	-702.45%		278.99%
Depreciation, Depletion And Amortization	$2.464M	$452.0K	$1.843M
YoY Change	33.7%		29.15%
Cash From Operating Activities	$55.06M	-$3.339M	$38.89M
YoY Change	41.57%		59.66%
INVESTING ACTIVITIES
Capital Expenditures	$547.0K	$0.00	$380.0K
YoY Change	43.95%		-93.34%
Acquisitions	$32.23M		$0.00
YoY Change
Other Investing Activities	-$32.23M	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$32.78M	$0.00	-$380.0K
YoY Change	8525.0%		-93.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$213.7M	-219.0K	-$767.0K
YoY Change	-27956.71%		-92.94%
NET CHANGE
Cash From Operating Activities	$55.06M	-3.339M	$38.89M
Cash From Investing Activities	-$32.78M	0.000	-$380.0K
Cash From Financing Activities	$213.7M	-219.0K	-$767.0K
Net Change In Cash	$235.9M	-3.558M	$37.74M
YoY Change	525.12%		385.08%
FREE CASH FLOW
Cash From Operating Activities	$55.06M	-$3.339M	$38.89M
Capital Expenditures	$547.0K	$0.00	$380.0K
Free Cash Flow	$54.51M	-$3.339M	$38.51M
YoY Change	41.55%		106.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001759655
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40365
CY2021	dei	Entity Registrant Name EntityRegistrantName	Privia Health Group, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3599420
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	950 N. Glebe Rd.,
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Arlington,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22203
CY2021	dei	City Area Code CityAreaCode	571
CY2021	dei	Local Phone Number LocalPhoneNumber	366-8850
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2021	dei	Trading Symbol TradingSymbol	PRVA
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	108168552	shares
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1420000000	USD
CY2021	dei	Auditor Firm AuditorFirmId	238
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	320577000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84633000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	117402000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	99118000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8697000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6333000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	446676000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	190084000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4502000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4814000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9634000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	59738000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5980000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	127938000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	118663000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	33364000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4953000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4521000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4475000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	239697000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	138885000	USD
CY2021Q4	us-gaap	Assets Assets	686373000	USD
CY2020Q4	us-gaap	Assets Assets	328969000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	45985000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	39252000	USD
CY2021Q4	prva	Physician And Practice Liability Current PhysicianAndPracticeLiabilityCurrent	140708000	USD
CY2020Q4	prva	Physician And Practice Liability Current PhysicianAndPracticeLiabilityCurrent	106811000	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	875000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	875000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2893000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	190461000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	146938000	USD
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	31688000	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	32784000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11043000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5595000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	45731000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	38379000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	236192000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	185317000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107837741	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107837741	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95985817	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95985817	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1078000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	960000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	633902000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	165666000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208108000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19878000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	426872000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	146748000	USD
CY2021Q4	us-gaap	Minority Interest MinorityInterest	23309000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	-3096000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	450181000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	143652000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	686373000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	328969000	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	966220000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	817075000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	786360000	USD
CY2021	prva	Physician And Practice Expense PhysicianAndPracticeExpense	727827000	USD
CY2020	prva	Physician And Practice Expense PhysicianAndPracticeExpense	629487000	USD
CY2020	prva	Unusual Or Infrequent Items Or Both Grants Received UnusualOrInfrequentItemsOrBothGrantsReceived	13300000	USD
CY2019	prva	Physician And Practice Expense PhysicianAndPracticeExpense	622632000	USD
CY2021	prva	Cost Of Platform CostOfPlatform	174731000	USD
CY2020	prva	Cost Of Platform CostOfPlatform	105006000	USD
CY2019	prva	Cost Of Platform CostOfPlatform	95256000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	22750000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11343000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9156000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	255884000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44016000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41827000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2464000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1843000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1427000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	1183656000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	791695000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	770298000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-217436000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	25380000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	16062000	USD
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1070000	USD
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1917000	USD
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6910000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-218506000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	23463000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9152000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27857000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7441000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1207000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-190649000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	30904000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	7945000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2419000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-340000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-299000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-188230000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	31244000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	8244000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.83
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.83
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102952370	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102952370	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95950062	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95950062	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95931549	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95931549	shares
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	86040000	USD
CY2019	prva	Adjustments To Additional Paid In Capital Capital Contribution AdjustmentsToAdditionalPaidInCapitalCapitalContribution	13264000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	207000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	7945000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	107456000	USD
CY2020	prva	Adjustments To Additional Paid In Capital Capital Contribution AdjustmentsToAdditionalPaidInCapitalCapitalContribution	4700000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	108000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	484000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	30904000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	143652000	USD
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9725000	shares
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	210994000	USD
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	2126924	shares
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3829000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	253531000	USD
CY2021	prva	Number Of Ms Os Where The Company Is At Lease The Majority Owner NumberOfMSOsWhereTheCompanyIsAtLeaseTheMajorityOwner	4	company
CY2021	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	28824000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-190649000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	450181000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-190649000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	30904000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	7945000	USD
CY2021	us-gaap	Depreciation Depreciation	1152000	USD
CY2020	us-gaap	Depreciation Depreciation	1188000	USD
CY2019	us-gaap	Depreciation Depreciation	784000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1312000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	642000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	643000	USD
CY2021	prva	Amortization Addition Of Debt Issuance Costs AmortizationAdditionOfDebtIssuanceCosts	157000	USD
CY2020	prva	Amortization Addition Of Debt Issuance Costs AmortizationAdditionOfDebtIssuanceCosts	134000	USD
CY2019	prva	Amortization Addition Of Debt Issuance Costs AmortizationAdditionOfDebtIssuanceCosts	332000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	253531000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	484000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	207000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-28411000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7834000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	716000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14642000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21779000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6178000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1269000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	962000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	151000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	9680000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1194000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2426000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1262000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9706000	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2079000	USD
CY2021	prva	Increase Decrease Physician And Practice Liability IncreaseDecreasePhysicianAndPracticeLiability	33897000	USD
CY2020	prva	Increase Decrease Physician And Practice Liability IncreaseDecreasePhysicianAndPracticeLiability	24542000	USD
CY2019	prva	Increase Decrease Physician And Practice Liability IncreaseDecreasePhysicianAndPracticeLiability	15571000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	13936000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-5538000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	672000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	4836000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	55058000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	38891000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	24358000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	547000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	380000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5709000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	32228000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32775000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-380000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5709000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	223685000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	12691000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2019	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	15250000	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	875000	USD
CY2021Q4	prva	Social Security Taxes Payable SocialSecurityTaxesPayable	800000	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	875000	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	30000000	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2019	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	35000000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3829000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	108000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	287000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	618000	USD
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	10000000	USD
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	10000000	USD
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	213661000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-767000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10868000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	235944000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37744000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7781000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84633000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46889000	USD
CY2021	prva	Management Services Organization Ownership Percentage ManagementServicesOrganizationOwnershipPercentage	1
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39108000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	320577000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84633000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46889000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	888000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1928000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	9200000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	504000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	381000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	316000	USD
CY2021	prva	Noncash Investing And Financing Activities Conversion Of Notes Payable To Related Parties To Capital Contribution NoncashInvestingAndFinancingActivitiesConversionOfNotesPayableToRelatedPartiesToCapitalContribution	0	USD
CY2020	prva	Noncash Investing And Financing Activities Conversion Of Notes Payable To Related Parties To Capital Contribution NoncashInvestingAndFinancingActivitiesConversionOfNotesPayableToRelatedPartiesToCapitalContribution	4700000	USD
CY2019	prva	Noncash Investing And Financing Activities Conversion Of Notes Payable To Related Parties To Capital Contribution NoncashInvestingAndFinancingActivitiesConversionOfNotesPayableToRelatedPartiesToCapitalContribution	13264000	USD
CY2021	prva	Number Of Markets In Which Entity Operates NumberOfMarketsInWhichEntityOperates	8	market
CY2021Q4	prva	Number Of Types Of Medical Groups NumberOfTypesOfMedicalGroups	3	group
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure. On an on-going basis we evaluate significant estimates and assumptions, including, but not limited to, revenue recognition, stock-based compensation, estimated useful lives of assets, intangible assets subject to amortization, and the computation of income taxes. Future events and their effects cannot be predicted with certainty; accordingly, the Company’s accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of the financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as the Company’s operating environment changes. Management evaluates and updates assumptions and estimates on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions.
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	prva	Unusual Or Infrequent Items Or Both Social Security Taxes Repayment Deferral Period UnusualOrInfrequentItemsOrBothSocialSecurityTaxesRepaymentDeferralPeriod	P2Y
CY2021	prva	Unusual Or Infrequent Items Or Both Social Security Tax Repayment Percent Remainder Of Fiscal Year UnusualOrInfrequentItemsOrBothSocialSecurityTaxRepaymentPercentRemainderOfFiscalYear	0.50
CY2021	prva	Unusual Or Infrequent Items Or Both Social Security Tax Repayment Percent Year One UnusualOrInfrequentItemsOrBothSocialSecurityTaxRepaymentPercentYearOne	0.50
CY2021	prva	Unusual Or Infrequent Items Or Both Grants Received UnusualOrInfrequentItemsOrBothGrantsReceived	800000	USD
CY2021	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	Impairment of Long-Lived Assets Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss can be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss is based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets during the years ended December 31, 2021 or 2020.
CY2021	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1200000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	800000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	1000000	USD
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	966220000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	817075000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	786360000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	117402000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	99118000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	404000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2759000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	127900000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	118700000	USD
CY2021Q4	prva	Number Of New Markets NumberOfNewMarkets	2	market
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	9300000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	118663000	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	9275000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	127938000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	64970000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5232000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9900000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3920000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5232000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3920000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	59738000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5980000	USD
CY2021	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P18Y11M1D
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3293000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3293000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3210000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3043000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3043000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	43856000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	59738000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5300000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1145000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2116000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2316000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.035
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2893000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2962000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2996000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2980000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2173000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1231000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15235000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	14090000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7801000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6987000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3299000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2173000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	27000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4502000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4814000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2973000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5235000	USD
CY2021Q4	prva	Accrued Employee Benefits And Compensation Current AccruedEmployeeBenefitsAndCompensationCurrent	7491000	USD
CY2020Q4	prva	Accrued Employee Benefits And Compensation Current AccruedEmployeeBenefitsAndCompensationCurrent	6167000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12292000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	10418000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	23229000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17432000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	45985000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	39252000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1100000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1900000	USD
CY2019	us-gaap	Interest Expense InterestExpense	4000000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	200000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	100000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	300000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	875000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	875000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1313000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1750000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	28437000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33250000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	345000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	363000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	492000	USD
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	345000	USD
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	363000	USD
CY2019	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	492000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	657000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-23650000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6440000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	546000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4552000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1364000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	169000	USD
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-28202000	USD
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-7804000	USD
CY2019	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	715000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27857000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7441000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1207000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10911000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9758000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	28767000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	33364000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	4953000	USD
CY2021Q4	prva	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2416000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2020Q4	prva	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	545000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	531000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42639000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10946000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	42639000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10946000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7980000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	5993000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1295000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9275000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5993000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	45500000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-45806000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4927000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1922000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	21399000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	124000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.098
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.014
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4280000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1426000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	901000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.061
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.098
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-13710000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2125000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.584
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.232
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	10000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-56000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.002
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	820000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-28000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	385000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.042
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27857000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7441000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1207000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.128
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.316
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.132
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	23.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0124
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	51700000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4016
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18300959	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.01
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M25D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3753317	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.15
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1935302	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.02
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	202772	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.87
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19916202	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.90
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M9D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	398117000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10826434	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.01
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y29D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	258296000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	253500000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	7100000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	93200000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	174600000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	253531000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	484000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	207000	USD
CY2021	prva	Defined Contribution Plan Employer Safe Harbor Contribution Percent DefinedContributionPlanEmployerSafeHarborContributionPercent	0.030
CY2020	prva	Defined Contribution Plan Profit Sharing Contribution Per Employee Percent DefinedContributionPlanProfitSharingContributionPerEmployeePercent	0.014
CY2019	prva	Defined Contribution Plan Profit Sharing Contribution Per Employee Percent DefinedContributionPlanProfitSharingContributionPerEmployeePercent	0.014
CY2021	prva	Defined Contribution Plan Profit Sharing Contribution Per Employee Percent DefinedContributionPlanProfitSharingContributionPerEmployeePercent	0.014
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2300000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2400000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2000000	USD
CY2021	prva	Number Of Institutions In Which Company Holds Its Cash And Cash Equivalents NumberOfInstitutionsInWhichCompanyHoldsItsCashAndCashEquivalents	2	institution
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-188230000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	31244000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	8244000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102952370	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102952370	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95950062	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95950062	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95931549	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95931549	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.83
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.83
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.33
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20901103	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18300959	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20901103	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17647833	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18300959	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17647833	shares

Files In Submission

Name	View Source	Status
0001759655-22-000032-index-headers.html	Edgar Link	pending
0001759655-22-000032-index.html	Edgar Link	pending
0001759655-22-000032.txt	Edgar Link	pending
0001759655-22-000032-xbrl.zip	Edgar Link	pending
exhibit-231xconsentofindep.htm	Edgar Link	pending
exhibit1020-noticeofmodifi.htm	Edgar Link	pending
exhibit104-parthmehrotrame.htm	Edgar Link	pending
exhibit106-thomasemploymen.htm	Edgar Link	pending
exhibit107-thomasemploymen.htm	Edgar Link	pending
exhibit108-thomasemploymen.htm	Edgar Link	pending
exhibit211-listofsubsidiar.htm	Edgar Link	pending
exhibit311-4q21.htm	Edgar Link	pending
exhibit312-4q21.htm	Edgar Link	pending
exhibit321-4q21.htm	Edgar Link	pending
exhibit322-4q21.htm	Edgar Link	pending
exhibit42descriptionofcapi.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
privialogo1a.jpg	Edgar Link	pending
privialogoa.jpg	Edgar Link	pending
prva-20211231.htm	Edgar Link	pending
prva-20211231.xsd	Edgar Link	pending
prva-20211231_cal.xml	Edgar Link	unprocessable
prva-20211231_def.xml	Edgar Link	unprocessable
prva-20211231_g1.jpg	Edgar Link	pending
prva-20211231_htm.xml	Edgar Link	completed
prva-20211231_lab.xml	Edgar Link	unprocessable
prva-20211231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRVA
Privia Health Group, Inc. Stock $prva

2021 Form 10-K Financial Statement

#000175965522000032 Filed on March 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRVA Privia Health Group, Inc. Stock $prva

2021 Form 10-K Financial Statement

#000175965522000032 Filed on March 25, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRVA
Privia Health Group, Inc. Stock $prva